Minneapolis, MN Clinical Trials Report — July 2026

Minneapolis participants should act quickly on studies nearing enrollment deadlines: 56 recruiting trials are expected to close within the next 90 days, including 4 that accept healthy volunteers. The city has 880 recruiting trials across 253 research facilities, so people with relevant conditions or those considering healthy-volunteer research have a broad local pool—but closing dates can arrive sooner if enrollment targets are reached.

July brought 6 new trials, down from 13 in May and 13 in June. New openings cover cancer, coronary artery disease, cystic fibrosis, obesity and overweight, radiation therapy, dietary intake, and limb-girdle muscular dystrophy type 2I/R9.

Closing-soon studies create the most immediate opportunities

Cancer-related enrollment deadlines are prominent among Minneapolis studies nearing closure. People seeking options should review eligibility and contact study teams promptly, particularly in these areas:

• Endometrial cancer (3 trials)
• Ovarian cancer (2 trials)
• Hodgkin lymphoma (2 trials)
• Prostate cancer (2 trials)
• Traumatic brain injury (2 trials)
• Obesity (2 trials)
• Chronic pain (2 trials)
• Amputation, advanced solid tumor, and acute myeloid leukemia (1 trial each)

Four of the closing-soon trials accept healthy volunteers. Across Minneapolis, 91 recruiting studies currently accept healthy volunteers, making the city a meaningful option for people without a diagnosed condition. Screening may still involve age requirements, health history, medication restrictions, laboratory testing, or time commitments.

New July studies include cystic fibrosis and a Phase 3 extension

The month’s six new openings include 3 drug trials, 1 behavioral study, 1 procedure study, and 1 study in another category. University of Minnesota sponsors 2 of the new studies. Other sponsors include Gila Therapeutics, Inc., Minneapolis Heart Institute Foundation, ML Bio Solutions, Inc., and Nicole Hamblett. Four studies are categorized as other-sponsored or academic activity, compared with 2 industry-sponsored trials.

• NCT07696338, “Rethinking Early Airway Clearence Therapies,” is a cystic fibrosis study sponsored by Nicole Hamblett. The REACT trial includes two parallel randomized studies, one evaluating hypertonic saline and the other evaluating dornase alfa. Planned enrollment is 405 participants.
• NCT07678775, “Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9,” is a Phase 3 study sponsored by ML Bio Solutions, Inc. It evaluates the long-term safety and efficacy of BBP-418 in eligible participants with limb-girdle muscular dystrophy type 2I/R9 who previously took part in the Fortify study. Planned enrollment is 107 participants.

Other new local categories include coronary artery disease, cancer, radiation therapy, obesity and overweight, dietary intake, and healthy volunteers. One of the six new trials accepts healthy volunteers, offering a fresh opportunity for people who do not have one of the medical conditions under study.

University of Minnesota is the city’s main research hub

The University of Minnesota leads Minneapolis by a wide margin, with 277 recruiting trials. Abbott-Northwestern Hospital follows with 90, while Hennepin County Medical Center has 74. These large institutions offer access across oncology, cardiovascular disease, neurology, behavioral health, and other specialties.

• University of Minnesota (277 trials)
• Abbott-Northwestern Hospital (90 trials)
• Hennepin County Medical Center (74 trials)
• University of Minnesota/Masonic Cancer Center (44 trials)
• Health Partners Inc (41 trials)
• Minneapolis VA Health Care System (26 trials)
• Children’s Hospitals and Clinics of Minnesota - Minneapolis (26 trials)
• Minneapolis Heart Institute Foundation (24 trials)
• Research Site (18 trials)
• Minneapolis Heart Institute (15 trials)
• Masonic Cancer Center (15 trials)
• University of Minnesota Medical Center (14 trials)

The University of Minnesota and its affiliated cancer centers are especially important starting points for people seeking oncology, rare-disease, and university-sponsored research. Abbott-Northwestern Hospital and the Minneapolis Heart Institute Foundation provide strong local visibility for cardiovascular studies, while Hennepin County Medical Center supports a broad range of patient-focused research. Children and families can also check Children’s Hospitals and Clinics of Minnesota - Minneapolis, since 2 of the new July trials include children.

Eligibility and timing for participants

Five of the new July studies include older adults. None is limited exclusively to women or men. The new-trial mix is split between studies involving industry sponsors and those categorized as other-sponsored or academic research. Healthy volunteers should search both the 91 currently recruiting studies and the four closing-soon studies, while patients with endometrial or ovarian cancer, lymphoma, prostate cancer, traumatic brain injury, obesity, or chronic pain should prioritize local screening now.

Nearby Minnesota alternatives

Participants willing to travel can also search nearby Minnesota cities. Rochester has 9 recruiting trials, while Edina, Mankato, Maplewood, and Saint Paul each have 1. Rochester is the clearest nearby alternative to Minneapolis for people whose eligibility, travel plans, or preferred specialty do not match an available city site.

Minneapolis’s new-trial count has moved from 10 in February to 13 in March, 17 in April, 16 in May, 13 in June, and 6 in July, with 2 recorded for August. As enrollment windows shift through the summer, checking both the large University of Minnesota network and nearby Rochester sites may reveal the best next opportunity.